$APG

APi’s (NYSE:APG) Q2 CY2026: Beats On Revenue, Stock Soars

APi (NYSE:APG) reported Q2 CY2026 revenue of $2.25 billion, up 13.3% year on year and 2.1% above Wall Street estimates, with non-GAAP EPS of $0.44 matching consensus and up from $0.39. Management guided next-quarter revenue to $2.4 billion (midpoint). The stock rose 7.2% to $41.24 after results.

Original reporting
Published Jul 30, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 1:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
APi’s (NYSE:APG) Q2 CY2026: Beats On Revenue, Stock Soars — source image
Decision brief

The 30-second read

$APGBullishMed
01

Why it matters

The key tradable change is the above-consensus next-quarter revenue guidance midpoint, alongside a Q2 revenue beat and an adjusted EPS beat, which together can drive revisions to near-term estimates.

02

Market read

A beat on Q2 revenue plus a surprisingly strong next-quarter revenue midpoint is the primary catalyst, aligning with a reported immediate 7.2% stock jump.

03

What to watch

Operating margin is only modestly improved and EPS growth is affected by share dilution, which can limit per-share upside even when revenue beats.

Relevance 8/10Novelty 7/10Timing: immediately following Q2 results, pre-market/early session reaction context

Background

APi is a life safety solutions and specialty services provider; the article frames its Q2 CY2026 performance versus analyst expectations and discusses revenue growth quality (organic vs headline).

Company-level read

Ticker impact

$APGBullishHigh confidence
Context

APi reported Q2 CY2026 revenue up 13.3% to $2.25B and guided next-quarter revenue to $2.4B midpoint, above expectations.

Expected impact

Likely supports continued upside bias in the near term, though follow-through depends on whether subsequent quarters sustain the guidance.

Evidence & confidence

The article provides concrete Q2 results, a specific next-quarter revenue midpoint, and notes the stock rose 7.2% immediately after results, indicating the market repriced the outlook.

Market effects

Signals strength in building life-safety and specialty services demand, potentially supportive for industrial services peers with similar end markets.

No explicit regional demand or macro linkage provided in the article.

No explicit international regulatory or global supply-chain catalyst described.

Counterpoint

Headline revenue outperformance may be partly helped by acquisitions and FX, so organic growth deceleration could reassert if guidance normalizes.

Key entities

  • APi

    Reported Q2 CY2026 revenue and adjusted EPS, and provided next-quarter revenue guidance above analyst expectations.

Related articles

$APGMed

APi Group Corp (APG) (Q2 2026) Earnings Call Highlights: Record Backlog Surpasses $5

APi Group (NYSE:APG) reported Q2 2026 earnings call highlights including a record backlog surpassing $5 billion. Management cited modest 10 bps adjusted EBITDA margin expansion, FX headwinds of about $30 million net revenue and $5 million adjusted EBITDA, and higher expected full-year interest expense to $150 million after a $500 million note issuance. CEO said project durations lengthened to 9-12 months, slowing backlog-to-revenue conversion.

$APGHigh

APi Group Corp (APG): Results of Operations and Financial Condition

APi Group Corp (APG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 APi Group Reports Record Second Quarter 2026 Financial Results and Raises Full-Year 2026 Outlook -Record second quarter net revenues of $2.3 billion, representing year-over-year growth of 13.3%, 10.1% on an organic basis- -Record second quarter reported net income of

$DOCUMedAI 8/10

DocuSign, Inc. Q2 2027 Earnings Call Summary

DocuSign reported Q2 2027 earnings, highlighting 15.1% ARR from Intelligent Agreement Management (IAM) platform, up from 12.6%. Revenue growth accelerated, with raised FY2027 ARR guidance to 8.5%-9.0%. IAM is expected to represent 18%-19% of total ARR by year-end. Gross margins may decline slightly due to cloud migration investments. The company plans continued share repurchases under its $2.1B authorization.

$MCKHighAI 8/10

McKesson Stock: Is MCK Outperforming the Healthcare Sector?

McKesson (MCK), a $107.4B healthcare distributor, has outperformed the sector, rising 24.6% in 3 months and 33.4% in 52 weeks. Q1 2027 revenue hit $105.4B, up 7.7% YoY, with adjusted EPS of $9.93. The company raised full-year EPS guidance to $44.60. Analysts rate MCK a 'Strong Buy' with a $984.29 price target.